4893 items matching your search terms.

Randomized trial of intrapatient dose escalation of single agent carboplatin as first-line treatment for advanced ovarian cancer: An SGCTG study (SCOTROC 4)

Kaye, SB Vasey, P Rustin, G Pledge, S Williams, C Gabra, H Skailes, G Lamont, A Lewsley, L Paul, J Scottish Gynaecological Cancer Trials Group,

Research profile: Professor Anthony Keech

Keech, AC

Use of PPAR agonists in the management and prevention of vascular disease in diabetes

Keech, A

Protection against nephropathy with fenofibrate in type 2 diabetes mellitus: the FIELD study

Keech, A Drury, P Davis, TM Donoghoe, M Laakso, M Whiting, M Scott, R D'Emden, MC on behalf of the FIELD study investigators,

Effects of fenofibrate on measures of renal function in type 2 diabetes mellitus: the FIELD study

Keech, A Drury, P Ting, R Davis, T Donoghoe, M Laakso, M Whiting, M Rajamani, K Scott, R D’Emden, M on behalf of the FIELD study investigators,

Cost-effectiveness considerations of cardiovascular therapeutics

Keech, A Horowitz, JD

Cost-effectiveness Considerations of Cardiovascular Therapeutics

Keech, A. Horowitz, J. D.
HEART LUNG AND CIRCULATION, 2009     DOI:10.1016/j.hlc.2008.11.006

Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial

Le Cesne, A Van Glabbeke, M Verweij, J Casali, PG Findlay, M Reichardt, P Issels, R Judson, I Schoffski, P Leyvraz, S Bui, B Hogendoorn, PCW Sciot, R Blay, JY
JOURNAL OF CLINICAL ONCOLOGY, 2009     DOI:10.1200/jco.2008.21.3330

Historical cross-trial comparisons for competing treatments in advanced breast cancer—an empirical analysis of bias

Lee, CK Lord, SJ Stockler, MR Gebski, V Coates, AS Simes, RJ on behalf of Australian and New Zealand Breast Cancer Trials Group (ANZ BCTG),

Molecular biomarkers to individualise treatment: assessing the evidence

Lee, C. Lord, S.J. Coates, A.S. Simes, R.J.

Outcomes of first-line chemotherapy for advanced breast cancer in women with good versus poor quality of life at baseline.

Lee, CK Stockler, M Gebski, V Coates, A Simes, RJ Australian New Zealand Breast Cancer Trials Group,

Predicting survival time in women starting first line chemotherapy for advanced breast cancer

Lee, CK Stockler, MR Hudson, M Coates, AS Gebski, V Lord, S Richard, SJ

Recurrent and injurious falls in the year following hip fracture: a prospective study of incidence and risk factors from the sarcopenia and hip fracture study

Lloyd, BD Williamson, DA Singh, NA Hansen, RD Diamond, TH Finnegan, TP Allen, BJ Grady, JN Stavrinos, TM Smith, EUR Diwan, AD Fiatarone Singh, MA

Using the principles of randomized controlled trial design to guide test evaluation

Lord, SJ Irwig, L Bossuyt, PMM
MEDICAL DECISION MAKING, 2009     DOI:10.1177/0272989x09340584

Using the principles of randomized controlled trial design to guide test evaluation

Lord, SJ Irwig, L Bossuyt, PMM